Physician profile
Robert S Fredericks
NPI 1336156546
$10,051.11
in general payments reported to CMS, 2019-2025
47 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $1,237 · 2021: $2,011 · 2022: $1,329 · 2023: $1,176 · 2024: $580 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307 · Education: $76.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,306.51 |
| Education | $76.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,981.59 | 2019-2024 | Rayaldee |
| Amgen INC. | $870.17 | 2019-2025 | Evenity, Repatha, Repatha |
| Corcept Therapeutics | $636.45 | 2019-2025 | Korlym |
| Esperion Therapeutics, INC. | $510.55 | 2021-2024 | Nexletol |
| Abbvie INC. | $504.79 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $493.40 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $480.95 | 2023-2025 | Yorvipath |
| Astrazeneca Pharmaceuticals Lp | $480.61 | 2019-2022 | |
| Lilly USA, LLC | $374.40 | 2019-2024 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $323.18 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $314.70 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $284.18 | 2023-2025 | Inpefa |
| Xeris Pharmaceuticals, INC. | $238.07 | 2020-2025 | Keveyis, Gvoke Hypopen |
| Radius Health, INC. | $233.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $193.93 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $182.92 | 2019-2022 | |
| Kyowa Kirin, INC. | $175.30 | 2023-2025 | Crysvita |
| Abbott Laboratories | $175.04 | 2021-2023 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $169.81 | 2024-2025 | Rezdiffra |
| Soleno Therapeutics, INC. | $162.91 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $129.11 | 2019-2022 | |
| Horizon Therapeutics Plc | $119.37 | 2022-2023 | Tepezza |
| Ferring Pharmaceuticals INC. | $114.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.83 | 2021 | |
| Alexion Pharmaceuticals, INC. | $97.08 | 2020-2023 | Strensiq |
| Beta Bionics, INC. | $73.37 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic, INC. | $68.41 | 2022-2025 | Inceptiv |
| Astellas Pharma US INC | $54.75 | 2024 | Veozah |
| Novo Nordisk INC | $51.72 | 2024-2025 | Sogroya |
| Recordati_rare_diseases_inc. | $51.69 | 2021-2023 | Isturisa, Signifor Lar |
| Shire North American Group INC | $48.72 | 2019 | |
| Sandoz INC. | $34.70 | 2025 | Omnitrope |
| Almatica Pharma LLC | $29.24 | 2024 | Teriparatide, Loreev Xr |
| Zealand Pharma US, INC. | $28.78 | 2021 | |
| Amryt Pharma Holdings Ltd | $28.03 | 2023 | Mycapssa |
| Ionis Pharmaceuticals, INC. | $26.95 | 2025 | Tryngolza |
| Alvogen INC | $22.93 | 2024 | Teriparatide |
| Nevro Corp. | $22.75 | 2024 | Senza |
| Renalytix Ai, INC. | $22.16 | 2022 | |
| Therapeuticsmd, INC. | $22.00 | 2019 | |
| Medicure Pharma INC. | $20.56 | 2021 | |
| Merck Sharp & Dohme LLC | $18.78 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.28 | 2021 | |
| Mannkind Corporation | $15.91 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.29 | 2022 | |
| Antares Pharma, INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fredericks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.